Table 4.

Serum Antirotavirus Immunoglobulin A Seroconversion Frequency, by Maternally Derived Antirotavirus Immunoglobulin G (IgG) Concentration Quartile 4 Weeks After the Final Vaccine Dose, and Baseline Geometric Mean Concentration (GMC) of Maternally Derived IgG

Variable	Group 1 (n = 142)	Group 2 (n = 139)	Group 3 (n = 143)
IgA seroconversion frequency, by maternally-derived IgG quartile
≤25th	14/36 (38.9a)	21/35 (60.0b)	19/36 (52.8c)
>25th to ≤50th	6/35 (17.1)	13/35 (37.1)	14/36 (38.9)
>50th to <75th	7/35 (20.0)	8/34 (23.5)	16/35 (45.7)
≥75th	2/36 (5.6)	10/35 (28.6)	13/36 (36.1)
Baseline GMC, U/mL (95% CI)	279.9 (237.2–330.4)	193.5 (163.9–228.1)	269.7 (232.6–312.8)

Data are no. of vaccine recipients who seroconverted/no. evaluated (%), unless otherwise indicated. Group 1 received rotavirus vaccine at ages 6 and 10 weeks, group 2 received vaccine at ages 10 and 14 weeks, and group 3 received vaccine at ages 6, 10, and 14 weeks.

Abbreviations: CI, confidence interval; IgA, immunoglobulin A.

^a P = .001, compared with the frequency among those with values in the 75th quartile.

^b P = .015, compared with the frequency among those with values in the 75th quartile.

^c P = .236, compared with the frequency among those with values in the 75th quartile.